According to filings with the U.S. Securities and Exchange Commission, Synnovation Therapeutics is raising $24,999,998.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Wenqing Yao played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers. We are dedicated to the discovery and development of best-in-class therapeutics that can improve the lives of people with cancer. Leveraging our deep expertise in medicinal chemistry, cancer biology and patient-focused precision medicine, we are building a diverse pipeline of novel small molecule targeted therapies. Our mission is to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.

To learn more about Synnovation Therapeutics, visit http://www.synnovationtx.com/

Contact:
Wenqing Yao, Chief Executive Officer
302-521-9490

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.